Summary
Boston Scientific Corporation reported solid financial results for the second quarter and first six months of 2022, demonstrating resilience and growth in a challenging economic environment. Net sales increased by 5.4% to $3.244 billion for the quarter and 7.6% to $6.270 billion for the six-month period, driven by strong operational performance in key segments like Urology & Pelvic Health and Cardiovascular, bolstered by strategic acquisitions. Despite headwinds from foreign currency fluctuations and inflationary pressures impacting gross profit margins, the company managed expenses effectively, leading to improved adjusted earnings per share. The company also made significant strategic moves, including the acquisition of Baylis Medical, which contributed to goodwill and intangible assets. While facing ongoing litigation expenses, particularly related to transvaginal surgical mesh products, Boston Scientific has made progress in resolving a substantial number of these cases. The company maintains a strong liquidity position, with ample cash and credit facilities, and remains committed to innovation and R&D investment to fuel future growth.
Financial Highlights
49 data points| Revenue | $3.24B |
| Cost of Revenue | $1.01B |
| Gross Profit | $2.23B |
| SG&A Expenses | $1.17B |
| Operating Expenses | $1.81B |
| Operating Income | $423.00M |
| Interest Expense | $64.00M |
| Net Income | $260.00M |
| EPS (Basic) | $0.17 |
| EPS (Diluted) | $0.17 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.44B |
Key Highlights
- 1Net sales for Q2 2022 increased by 5.4% year-over-year to $3.244 billion, and for the first six months of 2022 increased by 7.6% to $6.270 billion.
- 2Adjusted earnings per diluted share for Q2 2022 were $0.44, up from $0.40 in the prior year period.
- 3The company completed the acquisition of Baylis Medical Company Inc. in Q1 2022 for $1.471 billion, strengthening its electrophysiology and structural heart product portfolios.
- 4Gross profit margin for Q2 2022 was 68.8%, a slight decrease from 69.3% in Q2 2021, impacted by inflation on raw materials and manufacturing inefficiencies, though it improved to 68.6% for the first six months of 2022.
- 5Selling, general, and administrative expenses as a percentage of net sales decreased by 50 basis points in Q2 2022 compared to the prior year, indicating effective cost management.
- 6The company reported $155 million in commercial paper outstanding as of June 30, 2022, with $2.595 billion available under its $2.750 billion revolving credit facility, demonstrating a strong liquidity position.
- 7Litigation-related net charges were $42 million in Q2 2022, a significant decrease from $298 million in Q2 2021, reflecting progress in resolving outstanding legal matters.